TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27633250

Group type: EXPERIMENTAL
Intervention: Sembragiline (1 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sembragiline (lower doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (healthy elderly subjects)
Number of subjects: 16
Study: 26200038

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 124
Study: 21517701

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18, 36 or 72 mg/day
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 21673083

Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Therapy (OMT) protocol consisting of myofascial release of the thoracic inlet, pectoral traction, rib raising, thoracic pump, and abdominal pump for 15 minutes.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group engaged in conversation with the researcher for 15 minutes.
Number of subjects: 21
Study: 18583105

Group type: EXPERIMENTAL
Intervention: WHO depression guideline with one day training
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: WHO depression guideline only (information group)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (uninformed)
Number of subjects: 497
Study: 16528977

Group type: EXPERIMENTAL
Intervention: Low HDL-cholesterol
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: High triglyceride
Number of subjects: 722

Group type: COMPARATOR
Intervention: Total cholesterol
Number of subjects: 722
Study: 12581034

Group type: EXPERIMENTAL
Intervention: Continuity of midwifery care from a group of seven midwives in collaboration with medical staff
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard care from a variety of midwives and medical staff
Number of subjects: 1000
Study: 15505943

Group type: EXPERIMENTAL
Intervention: Neuropsychological stimulation via hemisphere-specific stimulation using visual or tactile stimulation or modified text
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention
Number of subjects: 0
Study: 9432405

Group type: EXPERIMENTAL
Intervention: Cisplatin plus vindesine plus mitomycin C (PVM)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cisplatin plus vindesine plus ifosfamide (PVI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cisplatin plus vindesine (PV)
Number of subjects: 105
Study: 1576046

Group type: EXPERIMENTAL
Intervention: Moxonidine (200 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxonidine and Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine, Moxonidine, and Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study: 6419954

Group type: EXPERIMENTAL
Intervention: Nasal reconstructive surgery
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (observation without treatment)
Number of subjects: 79
Study: 29059377

Group type: EXPERIMENTAL
Intervention: Power setting at 10 W
Number of subjects: 21

Group type: COMPARATOR
Intervention: Power setting at 6 W
Number of subjects: 21
Study: 27178974

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention on cardiovascular risk factors in high-risk hypertensive patients (ESCAPE trial)
Number of subjects: 256
Study: 25038532

Group type: EXPERIMENTAL
Intervention: Two-step consent process (consented intervention arm participants for exams after randomization)
Number of subjects: 73036

Group type: EXPERIMENTAL
Intervention: Distance from screening centers
Number of subjects: 73036

Group type: EXPERIMENTAL
Intervention: Overall non-compliance rate
Number of subjects: 73036
Study: 23363713

Group type: EXPERIMENTAL
Intervention: Adding folic acid 5 mg/day and vitamin B(12) 500 µg twice daily (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adding folic acid 5 mg/day, vitamin B(12) 500 µg twice daily and probucol 500 mg twice daily (Group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard antihypertensive medication (Group 1)
Number of subjects: 120
Study: 20868458

Group type: EXPERIMENTAL
Intervention: risperidone (0.5‐2 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: divalproex (60‐120 μg/mL)
Number of subjects: 66
Study: 19288773

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention including domiciliary telesurveillance and telepsychology at home
Number of subjects: 0
Study: 16027128

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Social Behaviour and Network Therapy (SBNT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Training and supervision
Number of subjects: 76
Study: 12771007

Group type: EXPERIMENTAL
Intervention: Intracoronary propranolol (n=75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (n=75)
Number of subjects: 150
Study: 11829701

Group type: EXPERIMENTAL
Intervention: eptifibatide (two 180‐microg/kg boluses, 10 minutes apart, with a continuous infusion of 2.0 microg/kg per minute; n = 1040)
Number of subjects: 2064

Group type: COMPARATOR
Intervention: placebo (n = 1024)
Number of subjects: 2064
Study: 10350964

Group type: EXPERIMENTAL
Intervention: Modified therapeutic community (TC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard services (treatment-as-usual, TAU)
Number of subjects: 0
Study: 7872877

Group type: EXPERIMENTAL
Intervention: Model based on age and CNS score
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Training set
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Test set
Number of subjects: 300
Study: 2299802

Group type: EXPERIMENTAL
Intervention: Recombinant human Erythropoietin (rhEPO) 50 U/kg body wt
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human Erythropoietin (rhEPO) 80 U/kg body wt
Number of subjects: 20
Study: 7287240

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 37

Group type: COMPARATOR
Intervention: 250 mg methyldopa (or 500 mg if poor response)
Number of subjects: 37
Study: 31648455

Group type: EXPERIMENTAL
Intervention: Analgesic mixture of morphine, ropivacaine, epinephrine, ketorolac and betamethasone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Same volume of mixture without betamethasone
Number of subjects: 70
Study: 27720602

Group type: EXPERIMENTAL
Intervention: epinastine 0.05% ophthalmic solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: artificial tear fluid (control)
Number of subjects: 10
Study: 26484902

Group type: EXPERIMENTAL
Intervention: Latent variable delta
Number of subjects: 525

Group type: COMPARATOR
Intervention: Established cognitive and functional scales
Number of subjects: 525

Group type: COMPARATOR
Intervention: Homologs of delta based on reduced test batteries
Number of subjects: 525
Study: 25093912

Group type: EXPERIMENTAL
Intervention: 4000 IU of vitamin D(3) for 9 months
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 22963378

Group type: EXPERIMENTAL
Intervention: Exercise intervention (in- and outpatient) including strength, flexibility, and aerobic exercise, performed 5 times/week during hospitalization and a combination of supervised and home-based sessions using the Wii device for 10 weeks after discharge.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard protocol without any specific exercise program (Control group).
Number of subjects: 24
Study: 18814016

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 17294302

Group type: EXPERIMENTAL
Intervention: Mirror Trainer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pelvic Trainer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 30
Study: 15305311

Group type: EXPERIMENTAL
Intervention: GBE-GBE (continuation group)
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: GBE-NT (discontinuation group)
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: NT-GBE (new treatment group)
Number of subjects: 1570

Group type: COMPARATOR
Intervention: NT-NT (no treatment group)
Number of subjects: 1570
Study: 11584476

Group type: EXPERIMENTAL
Intervention: Intercessory prayer (IP)
Number of subjects: 219

Group type: COMPARATOR
Intervention: No intercessory prayer (no IP)
Number of subjects: 219
Study: 9512274

Group type: EXPERIMENTAL
Intervention: Coated, self-expanding metal stents
Number of subjects: 75

Group type: COMPARATOR
Intervention: Latex prostheses
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prior radiation and/or chemotherapy
Number of subjects: 75
Study: 8062521

Group type: EXPERIMENTAL
Intervention: rapeseed oil mayonnaise with a small dose of sitostanol ester (800 mg/day of sitostanol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rapeseed oil mayonnaise with a higher dose of sitostanol ester (2000 mg/day of sitostanol)
Number of subjects: 15

Group type: COMPARATOR
Intervention: rapeseed oil mayonnaise alone (control group)
Number of subjects: 15
Study: 3173998

Group type: EXPERIMENTAL
Intervention: 10 IU/cc heparin infusion
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 5 IU/cc heparin infusion
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 73
Study: 29325660

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard of care WIC Loving Support BFPC program (Control)
Number of subjects: 174
Study: 27575538

Group type: EXPERIMENTAL
Intervention: Thermal Balloon Ablation (TBA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vaginal Hysterectomy
Number of subjects: 40
Study: 24587338

Group type: EXPERIMENTAL
Intervention: Reporting accuracy of dietary intake
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Low energy reporters classification
Number of subjects: 161
Study: 22512264

Group type: EXPERIMENTAL
Intervention: Vildagliptin + Metformin
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo + Metformin
Number of subjects: 171
Study: 20810376

Group type: EXPERIMENTAL
Intervention: COPE intervention (up to 12 home or telephone contacts over 4 months)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (3 telephone calls and educational materials)
Number of subjects: 237
Study: 18172697

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) added to general practitioners' care
Number of subjects: 135

Group type: COMPARATOR
Intervention: General practitioners' care only
Number of subjects: 135
Study: 15669610

Group type: EXPERIMENTAL
Intervention: Human observer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ideal observer
Number of subjects: 0
Study: 16051958

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 710
Study: 10840409

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not treated surgically)
Number of subjects: 90
Study: 9101613

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (Child A and B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Child B patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 30
Study: 8222658

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing gestodene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triphasic oral contraceptive containing norethindrone
Number of subjects: 0
Study: 3467701

Group type: EXPERIMENTAL
Intervention: High calorie and protein clear fluid regime
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard clear fluids
Number of subjects: 16
Study: 3397253

Group type: EXPERIMENTAL
Intervention: rosaprostol
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 30125457

Group type: EXPERIMENTAL
Intervention: Marine n‐3 fatty acids (2.6 g daily for 44 weeks)
Number of subjects: 132
Study: 28479622

Group type: EXPERIMENTAL
Intervention: Socioeconomic support (conditional cash transfers up to 230 USD, community meetings, household visits)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Standard of care plus socioeconomic support
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 312
Study: 25311952

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 75
Study: 23351923

Group type: EXPERIMENTAL
Intervention: Semi-finished occlusal appliance (SB)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laboratory-made occlusal appliance (SS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conservative therapy (CO)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Semi-finished occlusal appliance (SB) and Laboratory-made occlusal appliance (SS)
Number of subjects: 63
Study: 21733177

Group type: EXPERIMENTAL
Intervention: High carbohydrate, low fat diet
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fat diet
Number of subjects: 370

Group type: COMPARATOR
Intervention: Non‐intervention control group
Number of subjects: 370
Study: 19287306

Group type: EXPERIMENTAL
Intervention: GSH 1500 mg/m before oxaliplatin infusion
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline solution before oxaliplatin infusion (Control)
Number of subjects: 27
Study: 16704986

Group type: EXPERIMENTAL
Intervention: Brassica Vegetable (BV) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Micronutrient and Fiber Supplementation (M+F) intervention
Number of subjects: 20
Study: 11812711

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection with 8 mL of 0.125% bupivacaine and 40 mg of methylprednisolone (20 mg/mL) at a rate of 6 mL/min.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Epidural infusion pressure measurement in DSD patients before treatment.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (patients with no history of back pain).
Number of subjects: 23
Study: 10075339

Group type: EXPERIMENTAL
Intervention: Reduced consumption of saturated fat and cholesterol (Intervention group, n = 540)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Control group (n = 522)
Number of subjects: 730
Study: 7555530

Group type: EXPERIMENTAL
Intervention: Enalapril (mean daily dose 35 +/- 11.4 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nifedipine (mean daily dose 50 +/- 12.9 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 102
Study: 2340615

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no beta-blockers)
Number of subjects: 42
Study: 7371971

Group type: EXPERIMENTAL
Intervention: Paper Pill (30 microgram ethinyloestradiol and 150 microgram levonorgestrel)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Microgynon 30 (conventional tablet formulation)
Number of subjects: 336
Study: 29689057

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS) intervention
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MN) supplementation
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Combined PS and MN
Number of subjects: 1419
Study: 28844318

Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (1 to 24 development units, DU)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (12 and 24 DU)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25679135

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study: 24047236

Group type: EXPERIMENTAL
Intervention: Training program (Staff as Change Agents - Enhancing and Sustaining Mental Health in Aged Care)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Training program and clinical support
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 18
Study: 21357377

Group type: EXPERIMENTAL
Intervention: Telomere length in peripheral blood leukocytes (longest quartile vs. shortest quartile)
Number of subjects: 3108

Group type: COMPARATOR
Intervention: Telomere length in peripheral blood leukocytes
Number of subjects: 3108
Study: 18705795

Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-sample t-test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-randomized studies
Number of subjects: 0
Study: 17557435

Group type: EXPERIMENTAL
Intervention: Tiagabine 4 mg
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Tiagabine 6 mg
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Tiagabine 8 mg
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Tiagabine 10 mg
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 15058157

Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication (0.15 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine premedication (0.15 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (oral or intramuscular)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral and intramuscular clonidine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine
Number of subjects: 102
Study: 11011346

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/d for 8 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/d plus Enalapril 5 mg/d for 8 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/d for 8 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/d plus Simvastatin 10 mg/d for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nitroglycerin (control)
Number of subjects: 38
Study: 8800119

Group type: EXPERIMENTAL
Intervention: 450 mg/day oral propafenone (Group 1)
Number of subjects: 47
Study: 1792326

Group type: EXPERIMENTAL
Intervention: Technique of set-up with fixed arm support (group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Technique of set-up without fixed arm support (group 1)
Number of subjects: 14
Study: 6407305

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole prophylaxis
Number of subjects: 47
Study: 31594876

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily for 1 month, followed by 80 mg daily for 23 months)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo (matched to simvastatin)
Number of subjects: 235
Study: 29866583

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography plus standard care
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard care without point-of-care ultrasonography
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography plus standard care (North America)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard care without point-of-care ultrasonography (North America)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography plus standard care (South Africa)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard care without point-of-care ultrasonography (South Africa)
Number of subjects: 273
Study: 27665091

Group type: EXPERIMENTAL
Intervention: EMLA (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 24030863

Group type: EXPERIMENTAL
Intervention: Primary PCI with bivalirudin, with or without intralesion abciximab and thrombus aspiration
Number of subjects: 451
Study: 24261227

Group type: EXPERIMENTAL
Intervention: Adaptol 1500-2000 mg/day for 30+2 days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Basic therapy only (Control)
Number of subjects: 94
Study: 20129356

Group type: EXPERIMENTAL
Intervention: HBO(2) preconditioning for two 30-min intervals at 2.4 ATA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: HBO(2) preconditioning
Number of subjects: 81
Study: 18392690

Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/day; n = 14)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day; n = 11)
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo (medical nutrition therapy; n = 10)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 35
Study: 15945501

Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide (pre-IB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide (post-IB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 16
Study: 12837435

Group type: EXPERIMENTAL
Intervention: tadalafil 20 mg
Number of subjects: 348

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 348
Study: 10440425

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily for 7 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment for 7 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atenolol (beta-blocker)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nifedipine (calcium uptake antagonist)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 22
Study: 8646251

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF) 30 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 29
Study: 1349486

Group type: EXPERIMENTAL
Intervention: sustained-release verapamil 200 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: conventional verapamil 120 mg t.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: beta-blockade and long-acting nitrates
Number of subjects: 20
Study: 3972657

Group type: EXPERIMENTAL
Intervention: Low dose rate radiotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventionally fractionated irradiation at normal high dose rate
Number of subjects: 48